Lower-dose immunosuppression plus hetrombopag for severe aplastic anemia in people 65 and older
Official title: Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe/Severe Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety
Run by Institute of Hematology & Blood Diseases Hospital, China · NCT07010237 · Data updated 2026-11-12
This study tests whether a lower-dose immunosuppressive regimen combined with hetrombopag can improve blood counts and safety for people aged 65 and older with severe or very severe aplastic anemia.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 65 (estimated) |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Drugs / interventions | cyclophosphamide |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | December 31, 2028 |
| Study ends | July 1, 2029 |
| Registry record updated | June 8, 2025 |
| Trial ID | NCT07010237 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 65 or older with confirmed very severe or severe aplastic anemia who can swallow oral medication and do not have disqualifying clonal cytogenetics, uncontrolled cancer, or severe organ dysfunction.
✕Probably not a fit
Patients with prior ATG or high-dose cyclophosphamide, prolonged prior cyclosporine/tacrolimus use, recent TPO-RA exposure longer than three months, active uncontrolled malignancy, severe organ failure, or disqualifying cytogenetic abnormalities are excluded and unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center, single-arm, open-label Phase IIB trial testing dose-attenuated immunosuppressive therapy (IST) combined with hetrombopag in patients aged 65 or older with very severe or severe aplastic anemia. Treatment consists of P-ATG 15 mg/kg IV daily for 5 days, cyclosporine 3 mg/kg/day adjusted to trough levels of 100–200 μg/L, and hetrombopag 15 mg daily. Participants are followed weekly for 24 weeks with a bone marrow evaluation at week 24 to document hematologic response and monitor safety. Key eligibility excludes clonal cytogenetic abnormalities (except isolated -Y or +8), prior ATG/high-dose cyclophosphamide, prolonged prior calcineurin inhibitor or TPO-RA use, uncontrolled malignancy, or severe organ dysfunction.
Why it matters
Potential benefit: If successful, this approach could increase response rates and reduce transfusion needs while offering a lower-toxicity option for older patients who tolerate standard IST poorly.
How similar studies have gone: Prior studies combining TPO-receptor agonists (such as eltrombopag) with standard IST have improved responses in SAA, but hetrombopag plus dose-attenuated IST specifically in elderly patients is less well studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of VSAA/SAA. * Age ≥65 years. * Completion of all screening assessments. * Must be able to swallow tablets. * Signed informed consent (by patient or legal guardian if patient is incapacitated). Exclusion Criteria: * Clonal cytogenetic abnormalities (excluding isolated -Y or +8). * Prior treatment with ATG/high-dose cyclophosphamide. * Prior cyclosporine/tacrolimus use \>12 months. * Prior TPO-RA therapy \>3 months. * Uncontrolled malignancies or conditions contraindicating ATG. * Severe organ dysfunction (e.g., creatinine ≥177 μmol/L). * Investigator judgment of unsuitability.
Where it's running
-
Red Blood Cell Diseases Center
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Principal investigator: Jun Shi, PhD — Institute of Hematology & Blood Diseases Hospital, CAMS
- Study coordinator: Jianping Li, MD
- Email: lijianping@ihcams.ac.cn
- Phone: +8613820961539
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dignity Therapy for Older Adults in Long-Term Care
This study tests dignity therapy to help people 65 and older in long-term care see their lives as meaningful and preserve their sense of self.
-
Intravenous iron to improve quality of life in older adults after acute coronary syndrome
This trial will try a single dose of intravenous ferric carboxymaltose in people 65 and older with iron deficiency after an acute coronary event to see if it improves quality of life and reduces frailty and adverse outcomes over 12 months.
-
Continuous monitoring and stepwise control of laryngeal mask airway cuff pressure to reduce throat problems after surgery in older adults
This trial will test whether continuously monitoring and progressively adjusting the inflatable laryngeal mask airway (LMA) cuff pressure reduces postoperative sore throat and swallowing problems in people aged 60 or older having elective non-thoracic, non-head-and-neck surgery.
-
Dynamic versus isometric strength training for older adults with high blood pressure
This project will try dynamic and isometric strength exercises to see if they lower blood pressure and improve mental and muscle health in older adults with hypertension who take blood pressure medication.
-
Predicting function and quality-of-life decline after curative surgery for gastrointestinal cancer in people over 65
This project will try to see which pre- and perioperative factors predict loss of independence and worse quality of life over one year in people aged 65 and older who have curative surgery for gastrointestinal cancers.
-
Caregiver support at different stages of Alzheimer's disease
This project uses questionnaires to see how family caregivers help people aged 60 and older with Alzheimer's disease at different stages and what that care costs.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.